Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume38.03K
Average Volume (3M)988.87K
Market Cap
AU$8.85M
Enterprise ValueAU$8.07M
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt reduces fixed financial obligations and interest burden, giving management structural flexibility to pursue R&D, licensing deals or bridge financing. Over a 2–6 month horizon this lowers near-term default risk versus leveraged peers and preserves operational optionality.
Proprietary IP And PlatformOwnership of technology-based platforms and proprietary compounds provides durable competitive advantages: it enables licensing, creates barriers to entry, and supports margin capture via royalties. This underpins long-term commercialization potential if partners adopt the tech.
Diverse End-market ExposureAddressing agriculture, public health and pest-control markets spreads commercial risk and links the business to structural demand (food security, biosecurity). Multiple end-markets improve the chance of steady licensing opportunities and reduce reliance on a single sector.
Bears Say
Revenue CollapseRevenue dropping to zero is a material structural concern: it severs recurring royalty or licensing income and undermines proof of commercialization. Without revenue restoration, the firm remains dependent on external financing, constraining long-term organic growth and partner credibility.
Sustained Negative Cash FlowSeveral years of meaningful negative operating and free cash flow signal ongoing cash burn that will deplete reserves absent new income or funding. This persistent outflow limits ability to invest in trials, scale commercialization, and forces dilutive or costly financing decisions over the medium term.
Eroding Equity Base And Funding RiskA shrinking equity base reduces the company's loss-absorption capacity and heightens funding vulnerability. Material equity erosion increases dilution risk on future raises, weakens creditworthiness, and elevates the probability that sustaining operations will require significant new capital or strategic transactions.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$8.85M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 101 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Feb 23, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 305,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
-140.35%
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---